# A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms

> **NCT07200479** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (estimated)

## Conditions studied

- Relapsed/Refractory B-Cell Neoplasms

## Interventions

- **DRUG:** CAR T cells chimeric antigen receptor cells

## Key facts

- **NCT ID:** NCT07200479
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-30
- **Primary completion:** 2027-06-28
- **Final completion:** 2027-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07200479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07200479, "A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07200479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*